



10th Anniversary of Biomedicines – Therapeutic Targeting of Cellular Quality Control Mechanisms in Chronic Lung Diseases

Guest Editor:

Dr. Poornima Mahavadi

Center for Interstitial and Rare Lung Diseases, Department of Internal Medicine, Justus-Liebig University Giessen, 35392 Giessen, Germany

Deadline for manuscript submissions:

closed (15 November 2022)

Message from the Guest Editor

Efforts to understand human lung physiology have led to much rewarding progress in the last century. The identification of the relevant mechanisms underlying several lung pathologies has been a vital part of this progress. In this context, we have witnessed that the quality assurance mechanisms of a cell play vital roles in maintaining a strict balance between cell survival and cell death, as well as to systematically respond to external and internal stress, thereby deciding the pathological consequences of various lung diseases. Such quality control already begins at the level of cellular organelles, namely, the endoplasmic reticulum (ER), mitochondria, the proteasome or the lysosome, but all these mechanisms converge into two major cellular surveillance systems: the ubiquitin–proteasome system (UPS) and the autophagy–lysosome pathway. We appreciate such studies in cellular, pre-clinical or clinical models of chronic lung diseases and encourage investigators to submit original research articles as well as review articles.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)